Downhill running does not alter blood C1q availability or complement-dependent cytotoxicity of therapeutic monoclonal antibodies against haematological cancer cell lines in vitro

Downhill running does not alter blood C1q availability or complement-dependent cytotoxicity of therapeutic monoclonal antibodies against haematological cancer cell lines in vitro

Abstract Complement-dependent cytotoxicity (CDC) is a primary mechanism-of-action of monoclonal antibody (mAb) immunotherapies used to treat haematological cancers, including rituximab and daratumumab. However, mAb efficacy may be limited by reduced bioavailability of complement C1q – which activate...

Full description

Bibliographic Details
Main Authors: Harrison D. Collier-Bain, Frankie F. Brown, Adam J. Causer, Lois Ross, Daniela Rothschild-Rodriguez, Noah Browne, Rachel Eddy, Kirstie L. Cleary, Juliet C. Gray, Mark S. Cragg, Sally Moore, James Murray, James E. Turner, John P. Campbell
Format: Article
Language:English
Published: Nature Portfolio 2024-11-01
Series:Scientific Reports
Subjects:
Complement-dependent cytotoxicity
Immunotherapy
Exercise
Muscle damage
Complement C1q
Online Access:https://doi.org/10.1038/s41598-024-79690-8

Internet

https://doi.org/10.1038/s41598-024-79690-8

Similar Items